About us
We bring extensive experience in drug development and nuclear imaging agent discovery, from project initiation and candidate selection to preclinical, clinical development, and life‑cycle management. With a strong focus on neuroscience, neuroimmunology, and rare diseases, we have driven programs forward through scientific rigor, operational excellence, and clear, impactful decision-making.
We are strongly networked in chemical biology, medicinal chemistry and nuclear imaging agent discovery in Europe.
Our expertise extends across the China drug‑development ecosystem. We bring hands‑on experience working with Chinese biotech companies, conducting clinical studies in China, navigating regulatory interactions, and collaborating with leading local Key Opinion Leaders. This integrated experience uniquely positions us to support companies planning and executing clinical trials in China efficiently and confidently.
Get in touch today to discuss Lyxira Consulting’s tailored solutions and drive your business forward. We are ready to assist with any inquiries and ensure your consulting needs are addressed with quality and celerity.
Dr. Lixin Zhang Auberson, M.D., Ph.D
Founder and Chief Medical Officer
Nearly 20 years experience in clinical development, translational medicine and drug life-cycle management. Served as global clinical program lead for multiple companies including Novartis, UCB, Lundbeck and as CMO for a Chinese biotech company. Has end-to-end experience in drug development, successfully delivered multiple innovative projects through IND and registration.
Dr. Yves P. Auberson, Ph.D
Co-founder and Chief Scientific Officer
A scientific leader with >30 years in CNS drug discovery and PET/SPECT tracer development, led several programs delivering clinical candidates and first-in-human imaging agents.
Yves has an extensive scientific network across Europe. He is a former President and current Advisor to the European Federation for Medicinal chemistry and Chemical biology (EFMC) and President-elect of the Swiss Chemical Society.